Susana M. Campos

ORCID: 0000-0001-9672-473X · 2 papers in corpus

article 2021

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).

·doi:10.1200/jco.2021.39.15_suppl.tps5609

TPS5609 Background: Despite significant strides in understanding the molecular pathogenesis of EC, there remain few effective therapies for recurrent disease. Deeper insight into the roles of disordered tumor vasculature and HIF1α- and VEGF…

article 2010

Novel Mutations in Endometriosis-Associated Ovarian Cancers

·doi:10.1056/oh201010120000002

Although ovarian cancer is not the most prevalent of women's cancers, it is the most virulent because — in the absence of reliable screening tools to